Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.

Trial Profile

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms IIPOP
  • Most Recent Events

    • 06 Jun 2017 Results assessing the potential survival benefit of an immediate postoperative intraperitoneal immunotherapy using catumaxomab in patients with gastric peritoneal carcinomatosis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 10 Feb 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 05 Feb 2016 Planned primary completion date changed from 1 Nov 2014 to 1 Nov 2019, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top